Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Collier

Showing results (491-500 of 508) with videos related to

Pageof 51
Sort By:
Journal of Acquired Immune Deficiency Syndromes (1999)|November 5, 2020
Brief Report: Weight Gain Following ART Initiation in ART-Naïve People Living With HIV in the Current Treatment EraStephanie A Ruderman, Heidi M Crane, Robin M Nance, et al.
Journal of Neurovirology|July 11, 2013
Increases in brain white matter abnormalities and subcortical gray matter are linked to CD4 recovery in HIV infectionChristine Fennema-Notestine, Ronald J Ellis, Sarah L Archibald, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 2, 2014
Neurocognitive change in the era of HIV combination antiretroviral therapy: the longitudinal CHARTER studyRobert K Heaton, Donald R Franklin, Reena Deutsch, et al.
Plos One|September 4, 2019
Characterization of the complete mitogenome of Anopheles aquasalis, and phylogenetic divergences among Anopheles from diverse geographic zonesLuis Martinez-Villegas, Juliana Assis-Geraldo, Leonardo B Koerich, et al.
Neurology|December 8, 2010
HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER StudyR K Heaton, D B Clifford, D R Franklin, et al.
AIDS (London, England)|March 15, 2024
Impact of antiretroviral therapy during acute or early HIV infection on virologic and immunologic outcomes: results from a multinational clinical trialTrevor A Crowell, Justin Ritz, Lu Zheng, et al.
Journal of Neurovirology|December 22, 2010
HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictorsRobert K Heaton, Donald R Franklin, Ronald J Ellis, et al.
The Lancet. HIV|August 3, 2019
Third-line antiretroviral therapy in low-income and middle-income countries (ACTG A5288): a prospective strategy studyBeatriz Grinsztejn, Michael D Hughes, Justin Ritz, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 15, 2013
Trends and disparities in antiretroviral therapy initiation and virologic suppression among newly treatment-eligible HIV-infected individuals in North America, 2001-2009David B Hanna, Kate Buchacz, Kelly A Gebo, et al.
Journal of the International AIDS Society|August 30, 2022
Third-line antiretroviral therapy, including raltegravir (RAL), darunavir (DRV/r) and/or etravirine (ETR), is well tolerated and achieves durable virologic suppression over 144 weeks in resource-limited settings: ACTG A5288 strategy trialAnchalee Avihingsanon, Michael D Hughes, Robert Salata, et al.
Pageof 51

Showing results (491-500 of 508) with videos related to

Sort By:
Pageof 51
Journal of Acquired Immune Deficiency Syndromes (1999)|November 5, 2020
Brief Report: Weight Gain Following ART Initiation in ART-Naïve People Living With HIV in the Current Treatment EraStephanie A Ruderman, Heidi M Crane, Robin M Nance, et al.
Journal of Neurovirology|July 11, 2013
Increases in brain white matter abnormalities and subcortical gray matter are linked to CD4 recovery in HIV infectionChristine Fennema-Notestine, Ronald J Ellis, Sarah L Archibald, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 2, 2014
Neurocognitive change in the era of HIV combination antiretroviral therapy: the longitudinal CHARTER studyRobert K Heaton, Donald R Franklin, Reena Deutsch, et al.
Plos One|September 4, 2019
Characterization of the complete mitogenome of Anopheles aquasalis, and phylogenetic divergences among Anopheles from diverse geographic zonesLuis Martinez-Villegas, Juliana Assis-Geraldo, Leonardo B Koerich, et al.
Neurology|December 8, 2010
HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER StudyR K Heaton, D B Clifford, D R Franklin, et al.
AIDS (London, England)|March 15, 2024
Impact of antiretroviral therapy during acute or early HIV infection on virologic and immunologic outcomes: results from a multinational clinical trialTrevor A Crowell, Justin Ritz, Lu Zheng, et al.
Journal of Neurovirology|December 22, 2010
HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictorsRobert K Heaton, Donald R Franklin, Ronald J Ellis, et al.
The Lancet. HIV|August 3, 2019
Third-line antiretroviral therapy in low-income and middle-income countries (ACTG A5288): a prospective strategy studyBeatriz Grinsztejn, Michael D Hughes, Justin Ritz, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 15, 2013
Trends and disparities in antiretroviral therapy initiation and virologic suppression among newly treatment-eligible HIV-infected individuals in North America, 2001-2009David B Hanna, Kate Buchacz, Kelly A Gebo, et al.
Journal of the International AIDS Society|August 30, 2022
Third-line antiretroviral therapy, including raltegravir (RAL), darunavir (DRV/r) and/or etravirine (ETR), is well tolerated and achieves durable virologic suppression over 144 weeks in resource-limited settings: ACTG A5288 strategy trialAnchalee Avihingsanon, Michael D Hughes, Robert Salata, et al.
Pageof 51